Posted on

cbd oil aspergers

Cbd oil aspergers

People with ASD may also be affected by different responses to sensory inputs of sound and light. A proportion of patients with this condition may also have intellectual impairments. Impairments in each of these areas may range from mild to severe.

Approximately 1% of adults and children have this condition.

ASD can be diagnosed at any stage, particularly at times of increased stress or when entering different environments such as a new school. Half of all patients however are identified before turning two.

ASD can be sub-classified as one of the following conditions:

  • Autism
  • Asperger syndrome
  • Pervasive development disorder – not otherwise specified
  • Childhood disintegrative disorder
  • Rett syndrome

Autistic Spectrum Disorder (ASD) symptoms are normally present prior to three years of age, however ASD can become apparent at any stage of life. The symptoms may vary between individuals and those with minimal symptoms may be more likely to be identified at a later age than those with severe difficulties.

The symptoms of ASD can be grouped into four categories:

  • Social difficulties
  • Problems with language and communication
  • Limited imagination
  • Unusual behaviours

Depending on the type and severity of ASD other features may also be present

  • Intellectual impairment
  • Sleep problems
  • Reading problems
  • Excelling in specific skills in a narrow domain i.e. in memory, music

The cause for Autistic Spectrum Disorders (ASD) is not fully known.

It has been proposed that there is a genetic component to developing ASD, the exact contribution of genetics to ASD however is unknown.


Diagnosis of Autistic Spectrum Disorder (ASD) is made as part of a longitudinal process of assessing a child or in some cases teenager or adult.

If as an individual/parent you are concerned that you/your child displays any of the symptoms associated with ASD the first port of call should be your general practitioner (GP).

The formal diagnosis of ASD is made by a specialist in the condition alongside a multi-disciplinary team by comparing an individual’s symptoms against a list of diagnostic criteria.

Autistic Spectrum Disorder Treatment

Children with Autistic Spectrum Disorder (ASD) are usually under the care of a paediatrician and multi-disciplinary team of speech and language therapists, occupational therapists, and psychologists.

The mainstay of treatment is educational support within the domains that they find most challenging, which may include social difficulties, language and communication, limited imagination or unusual behaviours.

Specific psychological behavioural therapy may be used to help reduce the incidence of challenging behaviours.

In addition, medication can be considered to help with the treatment of specific symptoms of anxiety, depression or obsessive-compulsive disorder if these remain uncontrolled by other methods. Medication is also used to help control behavior such as aggression and improve sleep.

Medicinal cannabis can be considered when first line therapies have not achieved adequate symptom control.

Cbd oil aspergers People with ASD may also be affected by different responses to sensory inputs of sound and light. A proportion of patients with this condition may also have intellectual

Cannabinoids and autism spectrum disorder (ASD)

By Mariano Garcia de Palau

Born in Barcelona, 17 February 1956. Graduated in medicine and surgery from the University of Barcelona in 1979. For 38 years has worked as an emergency physician in the area of occupational medicine. He became interested in cannabis by chance, and for the last 15 years has studied its therapeutic uses. He currently works at Kalapa Clinic, where he advises on treatments with cannabinoids, performs clinical work with patients and collaborates with different organisations and associations such as Catfac. He is a member of the Spanish Observatory for Medicinal Cannabis. He is a regular member of IACM.

Autism can be described as a disorder of neurodevelopment, causing alterations in social interaction and with the subject’s surroundings. It also causes problems with verbal and non-verbal communication, and sometimes very restricted and usually repetitive behaviour.

Parents usually start to become aware of these features during the first two years of life. However, this may depend on the degree of autism, which can vary from very mild in some cases to extreme in others.

This variability —as well as other features discussed below— has led to the development of the concept of Autism Spectrum Disorder (ASD). This category encompasses three types of disorder with separate and distinguishable characteristics, namely autistic disorder, Asperger’s syndrome, and PDD-NOS (Pervasive Developmental Disorder-Not Otherwise Specified). Diagnosis can sometimes prove very difficult and be complicated by the degree of autism and a correlation with other pathologies, such as refractory epilepsy.

Autism per se (autistic disorder) involves retardation in cognitive development; this is not the case, however, with Asperger’s syndrome, where numerous cases have been reported of patients with above-average cognitive performance; some individuals are even exceptionally gifted at performing certain mental tasks.

The causes of this disorder are not known with any certainty. Although there are different theories, we do know that there is a proven genetic predisposition. ASD has been related to the so-called fragile X syndrome. However, it is not known whether other chromosomal changes might also be causes or contributors.

Other causes that have been reported include the MMR vaccine, use of paracetamol, food and environmental factors and celiac disease.

Neurotransmitters such as dopamine, serotonin, tryptophan and oxytocin might also be involved.

We know that the endocannabinoid system (ECS) is involved in regulating the processes that are altered in these disorders. One might therefore consider that phytocannabinoids (plant-extracted cannabinoids) might help treat the symptoms of ASD.

We can give some idea of what everyday life for autistic children and the people around them by describing their behavioural and empathic characteristics.

They reject physical contact; there is either no or only very brief eye contact; they do not respond to their parents’ facial gestures; they do not point to objects or actions to draw attention to them or look at objects that their parents point to; they do not properly use facial expressions to show feelings; they show no kind of concern for others; they normally do not have friends and show no interest in making them.

At 16 months, they are normally still unable to say isolated words. They do not point at objects they need or share with others. They tend to repeat what others say without understanding the meaning; they do not usually answer to their names, though they sometimes respond to other sounds. They appear to be uninterested in communicating.

In many cases, they make repetitive movements with their head, arms or hands and suck their fingers.

These children suffer great frustration because they cannot convey and express their emotions. In many cases they have no verbal language, but probably do want to communicate. Imagine living like that.

In cases of severe autism, many children and adolescents display unstable and aggressive behaviour, often including self-harming. This causes major problems for keeping them under control, often necessitating the use of neuroleptic drugs or benzodiazepines to solve behavioural issues.

Prospects for use of phytocannabinoids

As we have said, the ECS is involved in controlling these processes; as early as the foetal period it regulates the essential processes related to neuron differentiation and synapse positioning.

Some studies have shown that ECS CB1 receptors —the most common in the central nervous system— show functional alterations in the cerebral regions involved in autism, such as the hippocampus and basal ganglia.

If this is one of the causes (or a decisive factor) in ASD, the most appropriate cannabinoid might be thought to be THC, since there are also studies that implicate the CB2 receptor in ASD.

THC is the cannabinoid that acts by way of these two receptors, CB1 and CB2.

However, cannabidiol or CBD has been shown to be of great interest for intervention in ASD. Its mechanisms of action differ from those of THC, although they both act on GPR55 receptors and also on transient receptor potential vanilloid (TRPV). All of these receptors are also found in the central nervous system.

The effect of CBD is very unusual. As we have said, many children with ASD display aggressive behaviour and often self-harm. The “conduct normalising” effect is of great interest, since there are no signs of sedation; patients remain properly alert and have no difficulty remaining so. However, in many cases their behaviour is stabilised (though I must reiterate that it is always necessary to assess the severity of the patient’s condition).

Some patients acquire skills they had either lost or never had, such as getting dressed on their own, interacting with the tablet, listening to music and paying attention to their surroundings when out walking. They are less inclined to reject physical contact and may even give hugs, possibly for the first time in years. Their facial expressions improve and they can hold eye contact.

Many children with ASD seem to be unhappy and to be in constant pain or suffering. However, once they start treatment this situation appears to change — or at least improve. Some smile or even laugh!

These changes might seem trivial, but for the children’s parents, they are a major breakthrough and offer some glimmer of hope where none had previously existed.

No clinical trials are yet available to provide the necessary statistics on the effectiveness of cannabinoid use in ASD. Nor have any studies been conducted on prolonged medium and long term use of CBD or on potential unwanted consequences. However, for the moment CBD has shown to be safe and very untoxic. Indeed, no maximum dose has yet been identified.

We know, then, that both of these cannabinoids can be effective in cases of ASD. I think we now have to determine the most effective treatments, in terms of the ratio or proportion of THC to CBD which should be used.

Patients must not display any form of psychoactive effect from THC. Initially, CBD should be used. Only subsequently should we assess the need to add differing proportions of THC, until an improvement is achieved in different areas, depending in all cases on the patient’s evolution. Evidently, it is essential to assess the effectiveness of treatment and be vigilant for the possible appearance of any side effects.

Each case must be appraised on its own merits; no two patients are the same. It is also extremely important that clinical trials be conducted, to allow us to work with scientifically proven data. Although there is plenty of information available on cannabinoids, it is mostly based on preclinical data, essentially from animal experiments.

Autism can be described as a disorder of neurodevelopment, causing alterations in social interaction and with the subject's surroundings. It also causes problems with verbal and non-verbal communication, and sometimes very restricted and usually repetitive behaviour. Parents usually start to become aware of these features during the first two years of life. However, this may